TY - JOUR
T1 - Can oncology recapitulate paleontology? Lessons from species extinctions
AU - Walther, Viola
AU - Hiley, Crispin T.
AU - Shibata, Darryl
AU - Swanton, Charles
AU - Turner, Paul E.
AU - Maley, Carlo C.
N1 - Funding Information:
The work of C.T.H. is supported by a National Institute for Health Research Academic Clinical Fellowship. C.S. receives funding from Cancer Research UK, the Rosetrees Trust, the Breast Cancer Research Foundation, the Prostate Cancer Foundation, European Union Framework program 7 grants PREDICT and RESPONSIFY, and the European Research Council. The work of P.E.T. is supported in part by grants from the National Science Foundation (DEB‑1021243) and NIH (R01‑AI091646). The work of C.C.M. is supported in part by Research Scholar Grant #117209‑RSG‑09‑163‑01‑CNE from the American Cancer Society, NIH grants P01 CA91955, R01 CA149566, R01 CA170595 and R01 CA140657, and CDMRP Breast Cancer Research Program Award BC132057.
Publisher Copyright:
© 2015 Macmillan Publishers Limited.
PY - 2015/5/5
Y1 - 2015/5/5
N2 - Although we can treat cancers with cytotoxic chemotherapies, target them with molecules that inhibit oncogenic drivers, and induce substantial cell death with radiation, local and metastatic tumours recur, resulting in extensive morbidity and mortality. Indeed, driving a tumour to extinction is difficult. Geographically dispersed species of organisms are perhaps equally resistant to extinction, but >99.9% of species that have ever existed on this planet have become extinct. By contrast, we are nowhere near that level of success in cancer therapy. The phenomena are broadly analogous - in both cases, a genetically diverse population mutates and evolves through natural selection. The goal of cancer therapy is to cause cancer cell population extinction, or at least to limit any further increase in population size, to prevent the tumour burden from overwhelming the patient. However, despite available treatments, complete responses are rare, and partial responses are limited in duration. Many patients eventually relapse with tumours that evolve from cells that survive therapy. Similarly, species are remarkably resilient to environmental change. Paleontology can show us the conditions that lead to extinction and the characteristics of species that make them resistant to extinction. These lessons could be translated to improve cancer therapy and prognosis.
AB - Although we can treat cancers with cytotoxic chemotherapies, target them with molecules that inhibit oncogenic drivers, and induce substantial cell death with radiation, local and metastatic tumours recur, resulting in extensive morbidity and mortality. Indeed, driving a tumour to extinction is difficult. Geographically dispersed species of organisms are perhaps equally resistant to extinction, but >99.9% of species that have ever existed on this planet have become extinct. By contrast, we are nowhere near that level of success in cancer therapy. The phenomena are broadly analogous - in both cases, a genetically diverse population mutates and evolves through natural selection. The goal of cancer therapy is to cause cancer cell population extinction, or at least to limit any further increase in population size, to prevent the tumour burden from overwhelming the patient. However, despite available treatments, complete responses are rare, and partial responses are limited in duration. Many patients eventually relapse with tumours that evolve from cells that survive therapy. Similarly, species are remarkably resilient to environmental change. Paleontology can show us the conditions that lead to extinction and the characteristics of species that make them resistant to extinction. These lessons could be translated to improve cancer therapy and prognosis.
UR - http://www.scopus.com/inward/record.url?scp=84928823799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928823799&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2015.12
DO - 10.1038/nrclinonc.2015.12
M3 - Review article
C2 - 25687908
AN - SCOPUS:84928823799
SN - 1759-4774
VL - 12
SP - 273
EP - 285
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 5
ER -